Cargando…

94: ANTIBODY RESPONSE AFTER A BOOSTER DOSE OF SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS AND THOSE WITH CHRONIC LIVER DISEASES

Detalles Bibliográficos
Autores principales:	Chauhan, Mahak, Nzeako, Ihechiluru E., Li, Feng, Thuluvath, Paul J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212385/ http://dx.doi.org/10.1016/S0016-5085(22)60037-4

Ejemplares similares

Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases
por: Chauhan, Mahak, et al.
Publicado: (2022)

Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases
por: Thuluvath, Paul J., et al.
Publicado: (2021)

Mo1358: IMPACT OF SARS-COV-2 INFECTION ON RECIPIENTS OF LIVER TRANSPLANT. REPORT OF A MEXICAN COHORT.
por: Azamar-Llamas, Daniel, et al.
Publicado: (2022)

Su1497: EFFECT OF SARS COV-2 VACCINE IN IBD PATIENTS ON BIOLOGIC THERAPY INCLUDING LIVER TRANSPLANT RECIPIENTS.
por: Brezina, Jan, et al.
Publicado: (2022)

654: A THIRD DOSE OF SARS-COV-2 VACCINE YIELDS HIGH ANTIBODY LEVELS COMPARED TO TWO DOSE VACCINATION SCHEDULE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Quan, Joshua, et al.
Publicado: (2022)

Tu1551: PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFα OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRY
por: Zacharopoulou, Eirini, et al.
Publicado: (2022)

Sa1428: SARS-COV-2 INFECTION EVOKED HYPOALBUMINEMIA PREDICTS PROGRESSION TO CRITICAL ILLNESS IN PATIENTS WITH MILD TO SEVERE LIVER DISEASE
por: Nora, Ian, et al.
Publicado: (2022)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Mujukian, Angela, et al.
Publicado: (2022)

Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kappelman, Michael, et al.
Publicado: (2022)

731 FAILURE TO DEVELOP NEUTRALIZING ANTIBODIES FOLLOWING SARS-COV-2 INFECTION IN YOUNG PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING BIOLOGICS
por: Dailey, Joelynn, et al.
Publicado: (2021)

1162: SINGLE-CELL IMMUNE PROFILING AND REPERTOIRE ANALYSIS OF CONVALESCENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 ANTIBODY RESPONSE
por: Gubatan, John Mark, et al.
Publicado: (2022)

Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
por: Joergensen, Kristin K., et al.
Publicado: (2022)

Su1481: IMPACT OF IMMUNOSUPPRESSIVE THERAPIES ON ANTIBODY DECAY FOLLOWING MRNA VACCINATION TO SARS-COV-2 IN A PROSPECTIVE COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASES
por: Deepak, Parakkal, et al.
Publicado: (2022)

Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY
por: Li, Dalin, et al.
Publicado: (2022)

Sa1427: THE LONGTERM EFFECTS OF COVID-19 ON ELEVATED LIVER FUNCTION TESTS AND OUTCOMES
por: Shah, Pooja, et al.
Publicado: (2022)

Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients
por: Rabinowich, Liane, et al.
Publicado: (2022)

Su1067: LIVER ENZYMES ALTERATION BUT NOT GI SYMPTOMS ARE ASSOCIATED WITH DEATH IN MINORITY COVID-19 PATIENTS WITH CANCER
por: Oskrochi, Gholamreza, et al.
Publicado: (2022)

Sa1421: HOSPITALIZATIONS FOR ALCOHOLIC LIVER DISEASE DURING THE COVID-19 PANDEMIC INCREASED MORE FOR WOMEN, ESPECIALLY YOUNG WOMEN, COMPARED TO MEN.
por: Campbell, John P., et al.
Publicado: (2022)

Fr580 THE MICROBIOME AND SARS-COV-2: DAVID VERSUS A TINY GOLIATH
por: Hazan, Sabine, et al.
Publicado: (2021)

Fr006 IMPACT OF A SARS-COV2 INFECTION IN PATIENTS WITH CELIAC DISEASE
por: Elli, Luca, et al.
Publicado: (2021)

782 PERSISTENT GASTROINTESTINAL SYMPTOMS AND CHRONIC FATIGUE AFTER SARS-COV-2 INFECTION.
por: Noviello, Daniele, et al.
Publicado: (2021)

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19
por: Sultan, Shahnaz, et al.
Publicado: (2020)

Fr402 MELD-NA SCORE VERSUS SOFA SCORE AND APACHE II SCORE AS EARLY PREDICTORS OF MORTALITY IN COVID-19 PATIENTS WITH LIVER INVOLVEMENT
por: Gomez, Sandra R., et al.
Publicado: (2021)

Mo1620: ECTOPIC FAT DEPOSITION IN THE LIVER AND PANCREAS AND THE PRESENCE OF EXCESS VISCERAL ADIPOSE TISSUE SIGNIFICANTLY INCREASE HOSPITALISATION RISK FOLLOWING COVID-19.
por: Waddell, Tom H., et al.
Publicado: (2022)

Tu1110: EXPRESSION OF EPITHELIAL PROTEASES PREDICTS SARS-COV-2 ENTRY IN HUMAN ENTEROIDS
por: Alvarado, David M., et al.
Publicado: (2022)

Sa1273: ENTERIC NEURONAL VASOACTIVE INTESTINAL PEPTIDE MEDIATES SARS-COV-2 ASSOCIATED DIARRHEA
por: Balasubramaniam, Arun, et al.
Publicado: (2022)

AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy
por: Sultan, Shahnaz, et al.
Publicado: (2020)

Fr001 PROTON PUMP INHIBITOR AND RISK OF SARS-COV-2 INFECTION: A MULTI-CENTER EXPERIENCE
por: Silverman, Anna L., et al.
Publicado: (2021)

Sa126 TROPISM OF SARS-COV-2 FOR BARRETT'S ESOPHAGUS MAY INCREASE SUSCEPTIBILITY TO DEVELOPING COVID-19
por: Jin, Ramon, et al.
Publicado: (2021)

AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update
por: Sultan, Shahnaz, et al.
Publicado: (2021)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Su1496: SARS-COV-2 INFECTION IN IBD: PANDEMIC WAVES AND PREDICTORS OF SEVERE OR PERSISTENT COVID-19
por: Taxonera, Carlos, et al.
Publicado: (2022)

Sa1275: ASSOCIATED FACTORS WITH ACUTE DIARRHEA IN SARS-COV-2 INFECTION: A CASE-CONTROL STUDY
por: Tellez, Francisco A. Felix, et al.
Publicado: (2022)

Sa1060: SAFETY AND EFFICACY OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) PLACEMENT IN PATIENTS WITH SARS-COV-2 INFECTION
por: Ahmed, Zunirah, et al.
Publicado: (2022)

785 SARS-COV-2 INFECTS ENTEROCYTES IN VIVO AND CAN PERSIST UP TO 7 MONTHS FOLLOWING RESOLUTION OF SYMPTOMS
por: Tokuyama, Minami, et al.
Publicado: (2021)

Su102 DIFFERENCES IN INTESTINAL EPITHELIAL GENE EXPRESSION MODULATES SARS-COV-2 INFECTION IN HUMAN IBD ENTEROIDS
por: Alvarado, David M., et al.
Publicado: (2021)

1166: IN-PATIENT ANTIBIOTIC EXPOSURE PROMOTES SARS-COV-2 PERSISTENCE IN THE GI TRACT IN COVID-19 ADMITTED PATIENTS
por: Sharma, Ashok, et al.
Publicado: (2022)

Tu1108: INTERVAL CANCERS IN PATIENTS WITH HEREDITARY GASTROINTESTINAL SYNDROMES AFTER ONE YEAR OF THE SARS-COV-2 PANDEMIC
por: Barchi, Alberto, et al.
Publicado: (2022)

Fr003 TRUE PREVALENCE OF SARS-COV-2 INDUCED DIARRHEA AMONG YOUNG AND OLDER ADULTS: A MULTICENTER STUDY
por: Perisetti, Abhilash, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eiatvu3q8t7mhlmqinnkbsj6de